DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "MediPoint: Predictive Breast Cancer Gene Testing - APAC Analysis and Market Forecasts" report to their offering.
Breast cancer is the most common form of cancer in women in both the developed and developing world. The incidence of breast cancer is increasing due to the increased life span and increasing adoption of Western lifestyle risk factors. Predictive breast cancer gene tests can be used to identify women who are at increased risk of developing hereditary breast cancer. The Predictive Breast Cancer Gene Testing market has seen exponential growth in the US, dominated by Myriad Genetics. Gene testing in Europe is mostly carried out by the state funded health sector, but increasingly private companies are offering breast cancer gene tests to physicians. Myriad Genetics' position in the market is dependent on it being the leading provider of the most common breast cancer mutations. By the end of our forecast period, the competitive landscape will experience significant change due to the erosion of Myriad Genetics' position, as a result of the expiry of key patents, and the emergence of alternative molecular technologies.
This report focuses on the predictive breast cancer gene testing markets in Japan and future markets in China and India, and identifies unmet needs in the market, physician attitudes towards current gene testing, and the future of gene testing in the face of rapid technological advancement.
Key Topics Covered:
1 Tables & Figures
2 Introduction
3 Disease Overview
3.1 Breast Cancer
3.2 Anatomy and Physiology
3.3 Pathophysiology
3.4 Clinical Presentation
3.5 Clinical Outcomes
3.6 Epidemiology
3.7 Economic Impact
4 Competitive Assessment
5 Unmet Needs
5.1 Genetic Counseling
5.2 Price
5.3 Interpretation of Results
5.4 Efficacy of the BRAC Analysis Test
5.5 Database Transparency
5.6 Test Validation
5.7 Undiscovered Mutations
5.8 Simplification of the Testing Process
5.9 Test Report Formats
5.10 Data Security
6 Pipeline Products
6.1 Predictive Breast Cancer Gene Tests in Development
6.2 Breast Cancer Gene Expression Tests
6.3 Emerging Sequencing Technology
6.4 New Gene Discovery
7 Industry Overview
7.1 Breast Cancer Testing Trends
7.2 Testing Volumes
7.3 Market Access
7.4 Adoption of Breast Cancer Gene Testing
7.5 Role of Genetic Counseling
7.6 Gene Testing Laboratories
7.7 Reimbursement Trends
7.8 Regulatory Issues/Recalls
7.9 Mergers & Acquisitions and Key Partnerships
8 Current and Future Players
8.1 Overview
8.2 Trends in Corporate Strategy
8.3 Common Strengths, Weaknesses, Opportunities and Threats
8.4 Company Profiles
9 Market Drivers, Opportunities and Barriers
9.1 Market Drivers
9.2 Opportunities
9.3 Market Barriers
9.4 Substitutes
10 Country Outlooks and Forecasts
11 Appendix
Companies Mentioned
- 23AndMe
- ATS GeneTech
- Ambry Genetics
- BGI-Shenzhen
- Centogene AG (Centogene Rostock GmBH)
- Complete Genomics
- Illumina
- Life Technologies
- Myriad Genetics
- Navigenics (now Life Technologies)
- NewGene Ltd.
- PreventionGenetics
- Roche
- Sistemas Genomicos
For more information visit Research and Markets.
